Floatz logo

Loncastuximab Tesirine

B-Cell Non-Hodgkin Lymphoma

Explore 306 assets in B-Cell Non-Hodgkin Lymphoma →
Floatz Rating
B61/100
Confidence
Indicative
v0.2
Sponsor
University of Birmingham
Modality
antibody_drug_conjugate
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
46Moderate confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05991388CT.gov
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
—Recruiting———
NCT05453396CT.gov
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
—Terminated———
NCT06918912CT.gov
Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure
—Recruiting———
NCT05270057CT.gov
Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies
—Active Not Recruiting———
NCT04970901CT.gov
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
—Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · B-Cell Non-Hodgkin Lymphoma

AssetSponsorPhaseRating
Loncastuximab Tesirine (this asset)University of BirminghamP2/3B · 61
VindesineChildren's Cancer Group, ChinaP4BBB
Anti-Cd20/Cd3 Monoclonal Antibody Regn1979University of BirminghamP3BBB
CytarabineChildren's Cancer Group, ChinaP4BBB
CamustineFederal Research Institute of Pediatric Hematology, Oncology and ImmunologyP4BBB
IsocyclophosphamideShanghai Junshi Bioscience Co., Ltd.P4BBB
ZanubrutinibThe First Affiliated Hospital of Soochow UniversityP4BBB
Autologous Cd4+ And Cd8+ T Cells, Enriched From Peripheral Blood Mononuclear Cells (Pbmcs) Transduced With A Nonreplicative Self-Inactivating (Sin) Lentiviral Vector Encoding A Chimeric Antigen Receptor (Car) Consisting Of The Human Cd19-Specific Scfv, An Lgg4 Hinge Region, Cd28 Transmembrane Domain, Cd137 (4-1Bb) Co-Stimulatory Domain And Cd3 Zeta Signalling Domain, Under The Control Of A Hybrid Elongation Factor 1 Alpha (Ef1.Alpha.) And Human T Cell Leukemia Virus Type 1(Htlv-1) Regulatory Element Promoter And Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Element (Wpre). The Vector Genome Also Encodes A Truncated Human Epidermal Growth Factor Receptor (Egfrt) That Is Co-Expressed With The Car And Cleaved From It By The T2A Self-Cleaving Peptide. The Vector Genome Also Contains A Splice Donor, A Fragment Of Gag, A Rev Response Element (Rre), A Mutated Central Polypurine Tract (Cppt), And A Splice AcceptorRuijin HospitalP4BBB
cd19-ucartUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyP4BB

+42 more in the B-Cell Non-Hodgkin Lymphoma cohort

Other indications for Loncastuximab Tesirine

IndicationSponsorPhaseRating
Marginal Zone Lymphoma—P2CCC · 55
Relapsed/Refractory Diffuse Large B-Cell Lymphoma—P3CCC · 54
Primary Mediastinal Large B-Cell Lymphoma—P2CCC · 54

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Loncastuximab Tesirine in B-Cell Non-Hodgkin Lymphoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/loncastuximab-tesirine-b-cell-non-hodgkin-lymphoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →